For Technology Transfer Offices (TTO)

Is this university asset ready to license – or should you build and de-risk first?

Evidence Accelerator – University Edition™

Evaluate market attractiveness across four integrated dimensions, so your office has a defensible commercial picture before pharma BD conversations begin.

ASSESSMENT

Dimensions evaluated 4

Key deliverables 4

Recommendation License / Build

Whether the priority is indication sequencing, pharma licensing, or spinout timing, every answer starts in the same place. Evidence Accelerator – University Edition™ gives your teama defensible commercial picture before pharma BD conversations, investment discussions, or development decisions begin.

MedNavigate Assessment Framework

Four dimensions · one integrated read

Each engagement combines clinical, health-economic, payer, and IP-commercial perspectives – not a single specialty or internal advocay.



Epidemiology & Burden of Illness

Size the patient population, assess disease severity and economic burden, and map the patient journey to identify where unmet need is greatest.



Competitive Landscape

Review approved therapies, clinical pipeline, and the treatment algorithm to identify fit, lead indication, and achievable differentiation.



Payer & Market Access

Evaluate coverage policies, coding pathways, and evidence requirements to determine reimbursement feasibility and time to coverage.



IP Position & Freedom to Operate

Working alongside IP counsel, interpret patent landscape and FTO findings through a commercial lens to assess deal value.

License Now or Build and De-Risk First

The Scorecard behind the recommendation

Committing to the wrong path has a cost: licensing too early can lock in weak terms before value is proven, while spinning out too late can mean losing leverage — or the deal itself.

Ready for Pharma Licensing	Build Out & De-risk First
Clear patient population with confirmed differentiation	Patient population and unmet need are still being defined
Proof-of-concept data supports competitive differentiation	Data are too early for pharma BD conversation
Strong IP with FTO confirmed in the target indication	IP position needs strengthening before licensing
Payer coverage pathway is established or achievable	Coverage pathway unclear; evidence requirements remain unmet
Market size and competitive fit are visible to a BD team	Indication sequencing and market positioning need further work

Why the TTOs Use it

Clarity before the path is committed



Independent validation

A read that isn’t a single consultant’s specialty, internal advocacy, or faculty assumptions.



Board-ready findings

Output built for institutional review, investor conversation, or pharma BD – not a raw data dump.



Leverage at the table

Know the recommendation before terms ar set, so licensing conversations start from evidence, not hope.